Fri, 04/24/2009 - 12:26
Jiangbo Pharma aims high as health care reform rolls out - CFO
by Karl Zhong
Elsa Sung, chief financial officer of Jiangbo Pharmaceuticals Inc., spoke to Interfax about the company's short and long-term strategies for success as China's health care reform kicks offs.
Two of the TCM medicines in particular, a drug to treat bone marrow inflammation and a cough suppressant, have great market potential.
- Elsa Sung, chief financial officer of Jiangbo Pharmaceuticals Inc.
Shanghai. April 24. INTERFAX-CHINA - Jiangbo Pharmaceuticals Inc., a U.S.-incorporated pharmaceutical company that operates primarily in China and was formerly known as Genesis Pharmaceuticals Enterprises Inc., is well positioned to benefit from the health care reform given its sound pharmaceutical marketing network and expanded product portfolio, according to Elsa Sung, the company's chief financial officer.
